This content is from: Premium
Casdin Leads a Biopharma Surge
Several funds that lost large amounts last year rebounded nicely in the first month of 2023.
Finally some good news for investors in Casdin Capital. The firm’s biopharma hedge fund posted a 20 percent gain in January, an encouraging start to the year in what was a mixed month for the strategy in general. Casdin, however, has a long
To continue reading, subscribe now to Premium Journalism. Already a subscriber? Login.